Intra-Cellular Therapies (NASDAQ:ITCI) Earns Hold Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a report published on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on the company. Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their price […]
StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a report published on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on the company. Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their price […]
